{"ticker": {"uuid": "f2d8b40b-4f13-47b3-8175-933f14f78530", "symbol": "GUTS", "name": "Fractyl Health, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "H.C. Wainwright reiterates Buy on Fractyl Health stock at $8", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQLXhMYjBNNk9rQVhjeFdqUldfYmFJS2Y2ZXI1QjlZNGFNUjJLX0VleElvMmE5SEVIVG9MT2FqVHAxRUI0R0xMMVd1SkQzVkVhRkh2NmMxN09jb0hOV3hYZXUtVG8zaHhjR1dEMGZwV3dfV0NYUTNUNjRZSGZSdFE0YXVQUTY0UEtZbElpVFFxZmdRbC1WQjZPNjVBT3NYNnA4RVpHb2QxZG9KVWYwRF8zSm9pOFF6UkdS?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T17:20:04+00:00", "published_display": "15 Jul 2026 17:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars", "summary": "Fractyl Health announced positive one-year results from its REMAIN-1 study, showing that its investigational Revita DMR System helped patients maintain GLP-1-induced weight loss after discontinuing obesity drugs. The Revita treatment reduced weight regain by approximately 40% com", "url": "https://www.benzinga.com/news/health-care/26/07/60481411/fractyl-health-helps-maintain-weight-after-stopping-popular-obesity-drugs-stock-soars", "source_name": "Benzinga", "published_at": "2026-07-15T18:10:27", "published_display": "15 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$GUTS stock is up 9% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTnlsZThiNU0wYXBJaXowdWw3SXB0TURtRUpMcFJWNGdELWQ4cnE5SEhnV0N5REFnb2FjNF9QLWctQkFIclhLM29DdjNfY0w2RUJ3TXprVUNmZ0JneFZTZzVud3BuOUNUV1RlOHVncTJvRnNUSWRudFExemxkUFlQcnc0VHA1OERZU1RMcExDYmhHSEFhdndOSnU3cTZwRGs?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T14:58:00+00:00", "published_display": "15 Jul 2026 14:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl gains after data for Revita procedure (GUTS:NASDAQ)", "summary": "Fractyl Health's stock (GUTS) rose approximately 9% after the company announced positive one-year data for its Revita procedure. The procedure significantly reduced weight regain (by about 40%) in patients with obesity who had discontinued GLP-1 therapy. This suggests Revita coul", "url": "https://seekingalpha.com/news/4614097-fractyl-gains-data-revita-procedure", "source_name": "Seeking Alpha", "published_at": "2026-07-15T14:41:07", "published_display": "15 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 88, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s", "summary": "Fractyl Health announced that its Revita procedure helped patients maintain a significant portion of their GLP-1-induced weight loss after discontinuing the therapy. The REMAIN-1 midpoint cohort data showed up to 84% weight retention at one year compared to 46% in the sham group,", "url": "https://finance.yahoo.com/healthcare/articles/fractyl-health-says-revita-helped-130253985.html", "source_name": "Market source", "published_at": "2026-07-15T12:41:07", "published_display": "15 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl reports 7.8 percent weight regain with Revita", "summary": "Fractyl Health reported one-year REMAIN-1 data for its Revita treatment, showing 7.8% weight regain compared to 13% for sham, among participants who had previously lost weight with tirzepatide. Fractyl's shares rose 5% following the announcement. The company anticipates releasing", "url": "https://grafa.com/en/news/united-states/fractyl-revita-one-year-weight-maintenance-data", "source_name": "grafa.com", "published_at": "2026-07-15T10:24:00", "published_display": "15 Jul 2026 10:24", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After GLP-1 drugs stop, Revita retained up to 84% of weight loss", "summary": "Fractyl Health (GUTS) announced positive one-year data from its REMAIN-1 Midpoint Cohort, demonstrating that its Revita DMR System helped patients retain up to 84% of GLP-1-induced weight loss after discontinuing tirzepatide, compared to 46% for sham. The study showed Revita redu", "url": "https://www.stocktitan.net/news/GUTS/fractyl-health-reports-positive-randomized-data-from-remain-1-wpuk7e8defi0.html", "source_name": "Stock Titan", "published_at": "2026-07-15T09:41:07", "published_display": "15 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation", "summary": "Fractyl Health announced positive one-year results from its REMAIN-1 Midpoint Cohort, demonstrating that its Revita DMR System can help patients maintain significant weight loss after discontinuing GLP-1 therapies. The study showed that Revita reduced weight regain by approximate", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327527/0/en/fractyl-health-reports-positive-randomized-data-from-remain-1-midpoint-cohort-demonstrating-durable-weight-maintenance-one-year-after-glp-1-discontinuation.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T09:41:07", "published_display": "15 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (Nasdaq: GUTS) reports 1-year Revita weight maintenance data", "summary": "Fractyl Health (Nasdaq: GUTS) has reported positive one-year data from its REMAIN-1 Midpoint Cohort, evaluating the Revita DMR System for maintaining weight after GLP-1 therapy discontinuation in obese adults. The data showed that a single Revita procedure significantly reduced w", "url": "https://www.stocktitan.net/sec-filings/GUTS/8-k-fractyl-health-inc-reports-material-event-69ef9552471f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T09:41:07", "published_display": "15 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Fractyl Health, Inc. \u2013 NASDAQ:GUTS", "summary": "The article focuses on the \"Price to book forward\" financial metric for Fractyl Health, Inc. (NASDAQ: GUTS). It indicates that the company's financial data on this metric is made by humans and suggests that investors can find this information on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-GUTS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T23:46:31", "published_display": "14 Jul 2026 23:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apple Stock Hits a Record as the AI Memory Crisis Guts Cheap Phones", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBiSW5LSjEyLWp5dWtXSDlpZnpodlhkbjV1WDRiQTd2S190QVpSY1VUdVhYN1hVQ21KQVJoLU8tWGZCOXI3LVRlWDVsZ0kyQmVLWVREUk1UVzBCZ1EtMm9CR1Q5Tm9LWUpjZmw4?oc=5", "source_name": "BeInCrypto", "published_at": "2026-07-14T07:49:00+00:00", "published_display": "14 Jul 2026 07:49", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fractyl Health (GUTS) Stock Sees Fair Value Cut As Analysts Weigh Revita Opportunity", "summary": "Analysts have reassessed Fractyl Health (GUTS), significantly cutting its fair value estimate from US$7.44 to US$5.03 per share, with a new price target of US$4. This adjustment reflects renewed expectations regarding the Revita procedure's potential and the large number of GLP-1", "url": "https://finance.yahoo.com/markets/stocks/articles/fractyl-health-guts-stock-sees-210907954.html", "source_name": "Market source", "published_at": "2026-07-11T14:09:00", "published_display": "11 Jul 2026 14:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GUTS - Fractyl Health Inc Options", "summary": "This article provides a detailed financial overview of Fractyl Health Inc (GUTS), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst ratings. The company's stock closed at $0.7620 with a slight decrease, and its market ", "url": "https://finviz.com/stock?t=GUTS&p=d&ty=oc", "source_name": "Finviz", "published_at": "2026-07-05T15:09:47", "published_display": "05 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Price Target Announced at $4.00/Share by Craig-Hallum", "summary": "Craig-Hallum has initiated coverage on Fractyl Health (NASDAQ:FTYL) stock, setting a price target of $4.00 per share. This target suggests a potential upside of 11.23% from the stock's previous closing price of $3.59. The new coverage and price target come after a recent decline ", "url": "https://www.moomoo.com/news/post/72339647/fractyl-health-price-target-announced-at-4-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-02T14:40:38", "published_display": "02 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum initiates Fractyl Health stock coverage with buy rating", "summary": "Craig-Hallum has initiated coverage on Fractyl Health Inc (NASDAQ:GUTS) with a \"buy\" rating and a price target of $4.00, significantly above its current stock price. The firm believes Fractyl's Revita procedure, designed for weight maintenance after GLP-1 therapy discontinuation,", "url": "https://www.investing.com/news/analyst-ratings/craighallum-initiates-fractyl-health-stock-coverage-with-buy-rating-93CH-4770751", "source_name": "Investing.com", "published_at": "2026-07-02T01:40:41", "published_display": "02 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum initiates Fractyl Health stock coverage with buy rating By Investing.com", "summary": "Craig-Hallum has initiated coverage on Fractyl Health Inc (NASDAQ:GUTS) with a buy rating and a $4.00 price target, citing its potential in developing a procedure-based approach for obesity following GLP-1 discontinuation. The firm believes Fractyl's Revita solution addresses a s", "url": "https://m.in.investing.com/news/stock-market-news/craighallum-initiates-fractyl-health-stock-coverage-with-buy-rating-93CH-5478901?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-01T14:10:12", "published_display": "01 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Initiated at Buy by Craig-Hallum", "summary": "Craig-Hallum has initiated coverage on Fractyl Health with a Buy rating. This rating suggests a positive outlook for the company's stock from the investment firm. Financial details or price targets were not included in this brief announcement.", "url": "https://www.moomoo.com/news/post/72339648/fractyl-health-initiated-at-buy-by-craig-hallum?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-01T14:10:12", "published_display": "01 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Initiates Fractyl Health at Buy With $4 Price Target", "summary": "Craig-Hallum has initiated coverage on Fractyl Health with a Buy rating and a price target of $4. This new rating suggests a positive outlook on the company's stock from the investment firm.", "url": "https://www.moomoo.com/news/post/72331287/craig-hallum-initiates-fractyl-health-at-buy-with-4-price", "source_name": "Moomoo", "published_at": "2026-07-01T13:40:38", "published_display": "01 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health, Inc. Actuals & Estimates (NASDAQ:GUTS)", "summary": "This article provides an overview of Fractyl Health, Inc. (NASDAQ:GUTS) stock performance, financial estimates, and analyst forecasts. It covers the current stock price, recent changes, market capitalization, and upcoming earnings dates, alongside a Q&A section addressing common ", "url": "https://www.tradingview.com/symbols/NASDAQ-GUTS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:09:40", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GUTS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Fractyl Health, Inc. (GUTS) stock, including analyst price targets and predictions for 2027. It details recent stock performance, financial metrics like market capitalization and earnings, and technical analysis ratings. The content emphasizes ", "url": "https://www.tradingview.com/symbols/NASDAQ-GUTS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:21", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Inc (GUTS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Fractyl Health Inc (GUTS), noting its current financial score of 6.75, ranking it 218 out of 388 in the Biotechnology & Medical Research industry. While the company's financial status is described as robust, its operating efficiency i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-guts/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:18", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Inc (GUTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Fractyl Health Inc (GUTS), covering business segments, regional revenue, and profit contribution. However, the article explicitly states that the relevant data for these breakdowns have not yet been disclose", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-guts/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:59", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health director Ajay Royan buys $19,596 in company stock", "summary": "Fractyl Health director Ajay Royan purchased 23,000 shares of the company's common stock for $19,596 on June 12, 2026, increasing his direct holdings to 40,901 shares. Despite the stock gaining nearly 27% in the past week, it is down 62% over the last six months. Royan also has s", "url": "https://www.investing.com/news/insider-trading-news/fractyl-health-director-ajay-royan-buys-19596-in-company-stock-93CH-4743502", "source_name": "Investing.com", "published_at": "2026-06-16T07:09:22", "published_display": "16 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (NASDAQ: GUTS) director adds 23,000 shares in open-market buy", "summary": "Fractyl Health (NASDAQ: GUTS) director Ajay Royan purchased 23,000 shares of common stock in an open-market buy on June 12, 2026, at $0.852 per share. Following this transaction, Royan directly holds 40,901 common shares and has indirect beneficial ownership of over 6.4 million s", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-05cfd8fdc012.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:39:31", "published_display": "15 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchase: Director at $GUTS Buys 23,000 Shares | GUTS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOOEZmalhaMVRkY0NJc0M3Ym5UOTFuNGNSMG1CSDFrSTdXNnE4a195bl9RclduT2Rza2c3eW81TFhxakV5YWZWT3VaZjBmZlAxN3pJMjJWT0Fjc0p1UWFfTU9ZWkdBb0lwUE93VnJ2a281bDFpdlU5aGlyR2U2bi1tV01FTHhXVnhSWmVEeDQtbDNvMGY0eGpsMQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GUTS SEC Filings - Fractyl Health 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive list of SEC filings for Fractyl Health (GUTS), including 10-K, 10-Q, and 8-K forms, as well as insider trading disclosures. Recent filings highlight director appointments, stock option grants, and a special shareholder meeting to vote on Tranche", "url": "https://www.stocktitan.net/sec-filings/GUTS/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-13T10:40:20", "published_display": "13 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) awards 22,500 stock options to board director", "summary": "Fractyl Health (GUTS) has awarded 22,500 stock options to board director Samuel Conaway as compensation for his service. These options have an exercise price of $0.7318 per share and an expiration date of June 9, 2036. The options will vest in a single installment on the earlier ", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-8ae79d43ae17.html", "source_name": "Stock Titan", "published_at": "2026-06-12T17:41:35", "published_display": "12 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (NASDAQ: GUTS) 2026 meeting backs board and auditor", "summary": "Fractyl Health, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected three Class II directors\u2014Ian Sheffield, Marc Elia, and Clive Meanwell\u2014for three-year terms. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the company's inde", "url": "https://www.stocktitan.net/sec-filings/GUTS/8-k-fractyl-health-inc-reports-material-event-61e9db9abb93.html", "source_name": "Stock Titan", "published_at": "2026-06-12T05:40:20", "published_display": "12 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health director William Bradley buys $50,328 in stock", "summary": "Fractyl Health director William Bradley purchased 68,493 shares of the company's common stock for $50,328, increasing his direct holdings to 84,622 shares. This insider buying occurs as the stock trades near its 52-week low. Additionally, Bradley was granted 22,500 stock options ", "url": "https://m.investing.com/news/insider-trading-news/fractyl-health-director-william-bradley-buys-50328-in-stock-93CH-4738513?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-11T21:40:23", "published_display": "11 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) director buys stock and receives 22,500 options", "summary": "FRACTYL HEALTH, INC. director William Bradley reported an open-market purchase of 68,493 shares of Common Stock at approximately $0.7348 per share, increasing his direct holdings to 84,622 shares. Additionally, he received a grant of stock options for 22,500 shares with an exerci", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-b5df02307781.html", "source_name": "Stock Titan", "published_at": "2026-06-11T21:08:54", "published_display": "11 Jun 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (NASDAQ: GUTS) director buys shares and receives options", "summary": "Fractyl Health (NASDAQ: GUTS) director Ian Sheffield recently bought 35,000 shares of common stock at $0.7294 per share, bringing his direct holdings to 35,000 shares. Additionally, he was granted 22,500 stock options with an exercise price of $0.7318, set to vest in a single ins", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-1bdd45c37da1.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:23", "published_display": "11 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) director Marc Elia receives 22,500-share stock option grant", "summary": "Fractyl Health (GUTS) director Marc Elia was granted stock options for 22,500 shares as compensation for his board service. The options have an exercise price of $0.7318 per share and will vest in a single installment, contingent on his continued service. Following this grant, El", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-91f8ef0520d9.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:23", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let\u2019s Look At Funding", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNQ2Nob2F3UmREZWd1Y3lBNDlFbXpGV0dvbkRmY0doeHNDZ3pFa3A0QkVqZUtnNXBRN2NReGJfU2ozSnlNd0d3c0dQM25kYjRXTkxZSUxMZHlGQUUyWXFTT05yNXI1WFBHdXZYekk3V1laMlowdE1MSFVGYkNKTnpEVVhzNm9mU3FzZ2RCLXNuR3pWZUJESm03V0cwTFdpTkl6bUE?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Says One-Year Data Shows Revita Sustains Post-GLP-1 Weight Loss", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fractyl-health-says-one-data-121439603.html", "source_name": "MT Newswires", "published_at": "2026-06-04T12:14:39+00:00", "published_display": "04 Jun 2026 12:14", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita\u00ae Procedure", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fractyl-health-reports-positive-one-110000909.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T11:00:00+00:00", "published_display": "04 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fractyl-health-appoints-mike-zumdahl-110000924.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T11:00:00+00:00", "published_display": "01 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nearly 1M leave GLP-1 therapy monthly; Fractyl hires market-access lead", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZ1pLZ2tSa2V5Q3VXSEdTdnBybW4yQU1Na21KZjV5UHY0UkNZcGFPTk9nTzhwY0d2UjRYbHUwS0hFTFZZWmEwTWw5VFNFM2tZdjFhRHZvZWY5a25jeTRvVDJXcW1hXzhJRExsMXpoR1hDZ3owSHdhMmdDeElaTnhlOENJaTRuZEZWcWk1amRNZEJJQWxWZWNnM2s1YXpVSTFrQmxVTmJiMm5kT0pHUmFyeEdxRFcwU0ttZW5IenFjU2E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPeEVEOFQ1ZUhlZGhZaXBMMVloSEJLcVp4d1ZhQ3ZnZUhYbHB0VHMyc1hmZG5lT0xyRnRULUxtSndWRjQwLWQ1aWdTUnRvOFFNQ3NEYjdDMWIyczhqLVRGcjE2TXVBRkl2YVdycFRQTVk3a3M0bGs2ZlRsUGROXy16b0xqTlJnNWY4UVdkYVRpOXJQZlpTSmVQZw?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/look-fractyl-health-guts-valuation-131904067.html", "source_name": "Simply Wall St.", "published_at": "2026-05-14T13:19:04+00:00", "published_display": "14 May 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZ2lheXB0SlVOQlBpa3lhaENsN29vUHJnLXlrZXZXZ0tUNjRqOERxZWd0QVdoQ3pSaXBhVGQ2c3ZqYjFYWGpFNmJGSmJCVmhjRWZURnF1cXQwcHdEYmJMQ0tuYlh6bkwzSmt2RVN0LWUtS2tXTnpVMnprUXdoSFR5YlBJZVprNFljOGlfUFVvaHdyZnd2eTR4TTBFWU85aTR6cjNGTjhn?oc=5", "source_name": "TradingView", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPTDFScEFYLV83ZkRJMGdjUjBYNUt0TWFCZnY5REV4cUF4SXVSbjczTmhCNk9UX203MEc5RFFKNXRnM1YwRHNraGlGem40TGhIM04tQjBXOUE0YUR3bW41LVJPbmFEcjZndEpGbjhZeGExOEw1XzNtelJUaEpFdU5LbVk5akVDQWdjSm5rcDd1cE5NQXN0VU51a1dtT08zQThwTURiVlRaNDVJWGlad2Z5VVVGUFEwQXRWSkVPUG1yU1hHQXVwTUtLS0dabjd1Ml9pTmVfd3lYUXZvU0hTYWtvLVZWVHJGNTg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FRACTYL HEALTH ($GUTS) Releases Q1 2026 Earnings, Stock Rises | GUTS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQVkZIWnpaTUpGNGRDTDJLUmNsY0NZU2Q4TDRPTWs0MDVTTzk1emwzTmNyb2E0ZEItNXBHYk45R3hEZndCNVpMalBZMHF3UXBmblJ4Xy1RY3duaElnUE9RV0hNZGFsVG1aV09udzR6TXdnamZVUExWb2o5dGpWaW8yRm9pTWZybThFMXZLNlc5YmJLVGx5Y3R2NFBoV0ttZi1nRnZRNw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fractyl Health CEO to speak at BofA conference after May 12 Q1 update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVjNCSkZocVdRdjN0TFRlQ05rUnRhQkRHNE42ZXN6WElkbk1LanhtQzZfeVNMRUM3MDNYT3Ryc3FxTWV5V09wZFBRWjRjRW80c0RYVW13SWM4NzRRS1I5cnp4MEU3X3lXclFiaE1KYlRjTk9FRk51cHVzUnlpZHVzSGZTZ3gtWDNTZ3o2NGpaZ2FiS0RoZ2MteGtDRjBYMVBSSzVvU0FlVWpZQjUtZ2dJblVJZjJGb2h6YzBpRw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (Nasdaq: GUTS) faces Nasdaq minimum bid-price warning", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQVl80bi1oOW1VSXJ6UV9uNzlfNVFyM3R4YUhham5hcFc1UDAtRUFvb3h6eG5QNmtYNFBadnNIRERYQVRVNmU3ZHJ6eHhEYjVvMkpZUHBwVk1sMG45LTJUai1Dcy1SRG5WOW4yZnlrbjdvaXpTc1VQdHVfalRSU0N5Smt4WnFJTDJlejVuSTFwNVJuX3dDNktaS1AzbEtMN1BYeGNLVUNMdW5tWms?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health, Inc. (GUTS) Moves to Buy: Rationale Behind the Upgrade", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOTE5NSm5IU1Z0RzBlazVjVHBEaF9tMVBkUmE2bUwxczRWR3RsOTItYzlaNWZpS3Vsel9ScmNSZXBHWWttR082ZmtVVzlLalJsd1RZRFFQUFBSVVRyMVM0ckw2bEFmbU9Tdnp2Wld5eG9uNGhhYXkwbUI5dS05eGZyVQ?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "H.C. Wainwright reiterates Buy on Fractyl Health stock at $8", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQLXhMYjBNNk9rQVhjeFdqUldfYmFJS2Y2ZXI1QjlZNGFNUjJLX0VleElvMmE5SEVIVG9MT2FqVHAxRUI0R0xMMVd1SkQzVkVhRkh2NmMxN09jb0hOV3hYZXUtVG8zaHhjR1dEMGZwV3dfV0NYUTNUNjRZSGZSdFE0YXVQUTY0UEtZbElpVFFxZmdRbC1WQjZPNjVBT3NYNnA4RVpHb2QxZG9KVWYwRF8zSm9pOFF6UkdS?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T17:20:04+00:00", "published_display": "15 Jul 2026 17:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars", "summary": "Fractyl Health announced positive one-year results from its REMAIN-1 study, showing that its investigational Revita DMR System helped patients maintain GLP-1-induced weight loss after discontinuing obesity drugs. The Revita treatment reduced weight regain by approximately 40% com", "url": "https://www.benzinga.com/news/health-care/26/07/60481411/fractyl-health-helps-maintain-weight-after-stopping-popular-obesity-drugs-stock-soars", "source_name": "Benzinga", "published_at": "2026-07-15T18:10:27", "published_display": "15 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$GUTS stock is up 9% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTnlsZThiNU0wYXBJaXowdWw3SXB0TURtRUpMcFJWNGdELWQ4cnE5SEhnV0N5REFnb2FjNF9QLWctQkFIclhLM29DdjNfY0w2RUJ3TXprVUNmZ0JneFZTZzVud3BuOUNUV1RlOHVncTJvRnNUSWRudFExemxkUFlQcnc0VHA1OERZU1RMcExDYmhHSEFhdndOSnU3cTZwRGs?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T14:58:00+00:00", "published_display": "15 Jul 2026 14:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl gains after data for Revita procedure (GUTS:NASDAQ)", "summary": "Fractyl Health's stock (GUTS) rose approximately 9% after the company announced positive one-year data for its Revita procedure. The procedure significantly reduced weight regain (by about 40%) in patients with obesity who had discontinued GLP-1 therapy. This suggests Revita coul", "url": "https://seekingalpha.com/news/4614097-fractyl-gains-data-revita-procedure", "source_name": "Seeking Alpha", "published_at": "2026-07-15T14:41:07", "published_display": "15 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 88, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s", "summary": "Fractyl Health announced that its Revita procedure helped patients maintain a significant portion of their GLP-1-induced weight loss after discontinuing the therapy. The REMAIN-1 midpoint cohort data showed up to 84% weight retention at one year compared to 46% in the sham group,", "url": "https://finance.yahoo.com/healthcare/articles/fractyl-health-says-revita-helped-130253985.html", "source_name": "Market source", "published_at": "2026-07-15T12:41:07", "published_display": "15 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl reports 7.8 percent weight regain with Revita", "summary": "Fractyl Health reported one-year REMAIN-1 data for its Revita treatment, showing 7.8% weight regain compared to 13% for sham, among participants who had previously lost weight with tirzepatide. Fractyl's shares rose 5% following the announcement. The company anticipates releasing", "url": "https://grafa.com/en/news/united-states/fractyl-revita-one-year-weight-maintenance-data", "source_name": "grafa.com", "published_at": "2026-07-15T10:24:00", "published_display": "15 Jul 2026 10:24", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After GLP-1 drugs stop, Revita retained up to 84% of weight loss", "summary": "Fractyl Health (GUTS) announced positive one-year data from its REMAIN-1 Midpoint Cohort, demonstrating that its Revita DMR System helped patients retain up to 84% of GLP-1-induced weight loss after discontinuing tirzepatide, compared to 46% for sham. The study showed Revita redu", "url": "https://www.stocktitan.net/news/GUTS/fractyl-health-reports-positive-randomized-data-from-remain-1-wpuk7e8defi0.html", "source_name": "Stock Titan", "published_at": "2026-07-15T09:41:07", "published_display": "15 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation", "summary": "Fractyl Health announced positive one-year results from its REMAIN-1 Midpoint Cohort, demonstrating that its Revita DMR System can help patients maintain significant weight loss after discontinuing GLP-1 therapies. The study showed that Revita reduced weight regain by approximate", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327527/0/en/fractyl-health-reports-positive-randomized-data-from-remain-1-midpoint-cohort-demonstrating-durable-weight-maintenance-one-year-after-glp-1-discontinuation.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T09:41:07", "published_display": "15 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (Nasdaq: GUTS) reports 1-year Revita weight maintenance data", "summary": "Fractyl Health (Nasdaq: GUTS) has reported positive one-year data from its REMAIN-1 Midpoint Cohort, evaluating the Revita DMR System for maintaining weight after GLP-1 therapy discontinuation in obese adults. The data showed that a single Revita procedure significantly reduced w", "url": "https://www.stocktitan.net/sec-filings/GUTS/8-k-fractyl-health-inc-reports-material-event-69ef9552471f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T09:41:07", "published_display": "15 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Fractyl Health, Inc. \u2013 NASDAQ:GUTS", "summary": "The article focuses on the \"Price to book forward\" financial metric for Fractyl Health, Inc. (NASDAQ: GUTS). It indicates that the company's financial data on this metric is made by humans and suggests that investors can find this information on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-GUTS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T23:46:31", "published_display": "14 Jul 2026 23:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apple Stock Hits a Record as the AI Memory Crisis Guts Cheap Phones", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBiSW5LSjEyLWp5dWtXSDlpZnpodlhkbjV1WDRiQTd2S190QVpSY1VUdVhYN1hVQ21KQVJoLU8tWGZCOXI3LVRlWDVsZ0kyQmVLWVREUk1UVzBCZ1EtMm9CR1Q5Tm9LWUpjZmw4?oc=5", "source_name": "BeInCrypto", "published_at": "2026-07-14T07:49:00+00:00", "published_display": "14 Jul 2026 07:49", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) Stock Sees Fair Value Cut As Analysts Weigh Revita Opportunity", "summary": "Analysts have reassessed Fractyl Health (GUTS), significantly cutting its fair value estimate from US$7.44 to US$5.03 per share, with a new price target of US$4. This adjustment reflects renewed expectations regarding the Revita procedure's potential and the large number of GLP-1", "url": "https://finance.yahoo.com/markets/stocks/articles/fractyl-health-guts-stock-sees-210907954.html", "source_name": "Market source", "published_at": "2026-07-11T14:09:00", "published_display": "11 Jul 2026 14:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GUTS - Fractyl Health Inc Options", "summary": "This article provides a detailed financial overview of Fractyl Health Inc (GUTS), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst ratings. The company's stock closed at $0.7620 with a slight decrease, and its market ", "url": "https://finviz.com/stock?t=GUTS&p=d&ty=oc", "source_name": "Finviz", "published_at": "2026-07-05T15:09:47", "published_display": "05 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Price Target Announced at $4.00/Share by Craig-Hallum", "summary": "Craig-Hallum has initiated coverage on Fractyl Health (NASDAQ:FTYL) stock, setting a price target of $4.00 per share. This target suggests a potential upside of 11.23% from the stock's previous closing price of $3.59. The new coverage and price target come after a recent decline ", "url": "https://www.moomoo.com/news/post/72339647/fractyl-health-price-target-announced-at-4-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-02T14:40:38", "published_display": "02 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum initiates Fractyl Health stock coverage with buy rating", "summary": "Craig-Hallum has initiated coverage on Fractyl Health Inc (NASDAQ:GUTS) with a \"buy\" rating and a price target of $4.00, significantly above its current stock price. The firm believes Fractyl's Revita procedure, designed for weight maintenance after GLP-1 therapy discontinuation,", "url": "https://www.investing.com/news/analyst-ratings/craighallum-initiates-fractyl-health-stock-coverage-with-buy-rating-93CH-4770751", "source_name": "Investing.com", "published_at": "2026-07-02T01:40:41", "published_display": "02 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum initiates Fractyl Health stock coverage with buy rating By Investing.com", "summary": "Craig-Hallum has initiated coverage on Fractyl Health Inc (NASDAQ:GUTS) with a buy rating and a $4.00 price target, citing its potential in developing a procedure-based approach for obesity following GLP-1 discontinuation. The firm believes Fractyl's Revita solution addresses a s", "url": "https://m.in.investing.com/news/stock-market-news/craighallum-initiates-fractyl-health-stock-coverage-with-buy-rating-93CH-5478901?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-01T14:10:12", "published_display": "01 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Initiated at Buy by Craig-Hallum", "summary": "Craig-Hallum has initiated coverage on Fractyl Health with a Buy rating. This rating suggests a positive outlook for the company's stock from the investment firm. Financial details or price targets were not included in this brief announcement.", "url": "https://www.moomoo.com/news/post/72339648/fractyl-health-initiated-at-buy-by-craig-hallum?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-01T14:10:12", "published_display": "01 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Initiates Fractyl Health at Buy With $4 Price Target", "summary": "Craig-Hallum has initiated coverage on Fractyl Health with a Buy rating and a price target of $4. This new rating suggests a positive outlook on the company's stock from the investment firm.", "url": "https://www.moomoo.com/news/post/72331287/craig-hallum-initiates-fractyl-health-at-buy-with-4-price", "source_name": "Moomoo", "published_at": "2026-07-01T13:40:38", "published_display": "01 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health, Inc. Actuals & Estimates (NASDAQ:GUTS)", "summary": "This article provides an overview of Fractyl Health, Inc. (NASDAQ:GUTS) stock performance, financial estimates, and analyst forecasts. It covers the current stock price, recent changes, market capitalization, and upcoming earnings dates, alongside a Q&A section addressing common ", "url": "https://www.tradingview.com/symbols/NASDAQ-GUTS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:09:40", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GUTS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Fractyl Health, Inc. (GUTS) stock, including analyst price targets and predictions for 2027. It details recent stock performance, financial metrics like market capitalization and earnings, and technical analysis ratings. The content emphasizes ", "url": "https://www.tradingview.com/symbols/NASDAQ-GUTS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:21", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Inc (GUTS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Fractyl Health Inc (GUTS), noting its current financial score of 6.75, ranking it 218 out of 388 in the Biotechnology & Medical Research industry. While the company's financial status is described as robust, its operating efficiency i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-guts/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:18", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Inc (GUTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Fractyl Health Inc (GUTS), covering business segments, regional revenue, and profit contribution. However, the article explicitly states that the relevant data for these breakdowns have not yet been disclose", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-guts/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:59", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health director Ajay Royan buys $19,596 in company stock", "summary": "Fractyl Health director Ajay Royan purchased 23,000 shares of the company's common stock for $19,596 on June 12, 2026, increasing his direct holdings to 40,901 shares. Despite the stock gaining nearly 27% in the past week, it is down 62% over the last six months. Royan also has s", "url": "https://www.investing.com/news/insider-trading-news/fractyl-health-director-ajay-royan-buys-19596-in-company-stock-93CH-4743502", "source_name": "Investing.com", "published_at": "2026-06-16T07:09:22", "published_display": "16 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (NASDAQ: GUTS) director adds 23,000 shares in open-market buy", "summary": "Fractyl Health (NASDAQ: GUTS) director Ajay Royan purchased 23,000 shares of common stock in an open-market buy on June 12, 2026, at $0.852 per share. Following this transaction, Royan directly holds 40,901 common shares and has indirect beneficial ownership of over 6.4 million s", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-05cfd8fdc012.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:39:31", "published_display": "15 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchase: Director at $GUTS Buys 23,000 Shares | GUTS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOOEZmalhaMVRkY0NJc0M3Ym5UOTFuNGNSMG1CSDFrSTdXNnE4a195bl9RclduT2Rza2c3eW81TFhxakV5YWZWT3VaZjBmZlAxN3pJMjJWT0Fjc0p1UWFfTU9ZWkdBb0lwUE93VnJ2a281bDFpdlU5aGlyR2U2bi1tV01FTHhXVnhSWmVEeDQtbDNvMGY0eGpsMQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GUTS SEC Filings - Fractyl Health 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive list of SEC filings for Fractyl Health (GUTS), including 10-K, 10-Q, and 8-K forms, as well as insider trading disclosures. Recent filings highlight director appointments, stock option grants, and a special shareholder meeting to vote on Tranche", "url": "https://www.stocktitan.net/sec-filings/GUTS/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-13T10:40:20", "published_display": "13 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) awards 22,500 stock options to board director", "summary": "Fractyl Health (GUTS) has awarded 22,500 stock options to board director Samuel Conaway as compensation for his service. These options have an exercise price of $0.7318 per share and an expiration date of June 9, 2036. The options will vest in a single installment on the earlier ", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-8ae79d43ae17.html", "source_name": "Stock Titan", "published_at": "2026-06-12T17:41:35", "published_display": "12 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (NASDAQ: GUTS) 2026 meeting backs board and auditor", "summary": "Fractyl Health, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected three Class II directors\u2014Ian Sheffield, Marc Elia, and Clive Meanwell\u2014for three-year terms. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the company's inde", "url": "https://www.stocktitan.net/sec-filings/GUTS/8-k-fractyl-health-inc-reports-material-event-61e9db9abb93.html", "source_name": "Stock Titan", "published_at": "2026-06-12T05:40:20", "published_display": "12 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health director William Bradley buys $50,328 in stock", "summary": "Fractyl Health director William Bradley purchased 68,493 shares of the company's common stock for $50,328, increasing his direct holdings to 84,622 shares. This insider buying occurs as the stock trades near its 52-week low. Additionally, Bradley was granted 22,500 stock options ", "url": "https://m.investing.com/news/insider-trading-news/fractyl-health-director-william-bradley-buys-50328-in-stock-93CH-4738513?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-11T21:40:23", "published_display": "11 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) director buys stock and receives 22,500 options", "summary": "FRACTYL HEALTH, INC. director William Bradley reported an open-market purchase of 68,493 shares of Common Stock at approximately $0.7348 per share, increasing his direct holdings to 84,622 shares. Additionally, he received a grant of stock options for 22,500 shares with an exerci", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-b5df02307781.html", "source_name": "Stock Titan", "published_at": "2026-06-11T21:08:54", "published_display": "11 Jun 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (NASDAQ: GUTS) director buys shares and receives options", "summary": "Fractyl Health (NASDAQ: GUTS) director Ian Sheffield recently bought 35,000 shares of common stock at $0.7294 per share, bringing his direct holdings to 35,000 shares. Additionally, he was granted 22,500 stock options with an exercise price of $0.7318, set to vest in a single ins", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-1bdd45c37da1.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:23", "published_display": "11 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) director Marc Elia receives 22,500-share stock option grant", "summary": "Fractyl Health (GUTS) director Marc Elia was granted stock options for 22,500 shares as compensation for his board service. The options have an exercise price of $0.7318 per share and will vest in a single installment, contingent on his continued service. Following this grant, El", "url": "https://www.stocktitan.net/sec-filings/GUTS/form-4-fractyl-health-inc-insider-trading-activity-91f8ef0520d9.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:23", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let\u2019s Look At Funding", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNQ2Nob2F3UmREZWd1Y3lBNDlFbXpGV0dvbkRmY0doeHNDZ3pFa3A0QkVqZUtnNXBRN2NReGJfU2ozSnlNd0d3c0dQM25kYjRXTkxZSUxMZHlGQUUyWXFTT05yNXI1WFBHdXZYekk3V1laMlowdE1MSFVGYkNKTnpEVVhzNm9mU3FzZ2RCLXNuR3pWZUJESm03V0cwTFdpTkl6bUE?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Says One-Year Data Shows Revita Sustains Post-GLP-1 Weight Loss", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fractyl-health-says-one-data-121439603.html", "source_name": "MT Newswires", "published_at": "2026-06-04T12:14:39+00:00", "published_display": "04 Jun 2026 12:14", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita\u00ae Procedure", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fractyl-health-reports-positive-one-110000909.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T11:00:00+00:00", "published_display": "04 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fractyl-health-appoints-mike-zumdahl-110000924.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T11:00:00+00:00", "published_display": "01 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nearly 1M leave GLP-1 therapy monthly; Fractyl hires market-access lead", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZ1pLZ2tSa2V5Q3VXSEdTdnBybW4yQU1Na21KZjV5UHY0UkNZcGFPTk9nTzhwY0d2UjRYbHUwS0hFTFZZWmEwTWw5VFNFM2tZdjFhRHZvZWY5a25jeTRvVDJXcW1hXzhJRExsMXpoR1hDZ3owSHdhMmdDeElaTnhlOENJaTRuZEZWcWk1amRNZEJJQWxWZWNnM2s1YXpVSTFrQmxVTmJiMm5kT0pHUmFyeEdxRFcwU0ttZW5IenFjU2E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPeEVEOFQ1ZUhlZGhZaXBMMVloSEJLcVp4d1ZhQ3ZnZUhYbHB0VHMyc1hmZG5lT0xyRnRULUxtSndWRjQwLWQ1aWdTUnRvOFFNQ3NEYjdDMWIyczhqLVRGcjE2TXVBRkl2YVdycFRQTVk3a3M0bGs2ZlRsUGROXy16b0xqTlJnNWY4UVdkYVRpOXJQZlpTSmVQZw?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/look-fractyl-health-guts-valuation-131904067.html", "source_name": "Simply Wall St.", "published_at": "2026-05-14T13:19:04+00:00", "published_display": "14 May 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZ2lheXB0SlVOQlBpa3lhaENsN29vUHJnLXlrZXZXZ0tUNjRqOERxZWd0QVdoQ3pSaXBhVGQ2c3ZqYjFYWGpFNmJGSmJCVmhjRWZURnF1cXQwcHdEYmJMQ0tuYlh6bkwzSmt2RVN0LWUtS2tXTnpVMnprUXdoSFR5YlBJZVprNFljOGlfUFVvaHdyZnd2eTR4TTBFWU85aTR6cjNGTjhn?oc=5", "source_name": "TradingView", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPTDFScEFYLV83ZkRJMGdjUjBYNUt0TWFCZnY5REV4cUF4SXVSbjczTmhCNk9UX203MEc5RFFKNXRnM1YwRHNraGlGem40TGhIM04tQjBXOUE0YUR3bW41LVJPbmFEcjZndEpGbjhZeGExOEw1XzNtelJUaEpFdU5LbVk5akVDQWdjSm5rcDd1cE5NQXN0VU51a1dtT08zQThwTURiVlRaNDVJWGlad2Z5VVVGUFEwQXRWSkVPUG1yU1hHQXVwTUtLS0dabjd1Ml9pTmVfd3lYUXZvU0hTYWtvLVZWVHJGNTg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FRACTYL HEALTH ($GUTS) Releases Q1 2026 Earnings, Stock Rises | GUTS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQVkZIWnpaTUpGNGRDTDJLUmNsY0NZU2Q4TDRPTWs0MDVTTzk1emwzTmNyb2E0ZEItNXBHYk45R3hEZndCNVpMalBZMHF3UXBmblJ4Xy1RY3duaElnUE9RV0hNZGFsVG1aV09udzR6TXdnamZVUExWb2o5dGpWaW8yRm9pTWZybThFMXZLNlc5YmJLVGx5Y3R2NFBoV0ttZi1nRnZRNw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health CEO to speak at BofA conference after May 12 Q1 update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVjNCSkZocVdRdjN0TFRlQ05rUnRhQkRHNE42ZXN6WElkbk1LanhtQzZfeVNMRUM3MDNYT3Ryc3FxTWV5V09wZFBRWjRjRW80c0RYVW13SWM4NzRRS1I5cnp4MEU3X3lXclFiaE1KYlRjTk9FRk51cHVzUnlpZHVzSGZTZ3gtWDNTZ3o2NGpaZ2FiS0RoZ2MteGtDRjBYMVBSSzVvU0FlVWpZQjUtZ2dJblVJZjJGb2h6YzBpRw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health (Nasdaq: GUTS) faces Nasdaq minimum bid-price warning", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQVl80bi1oOW1VSXJ6UV9uNzlfNVFyM3R4YUhham5hcFc1UDAtRUFvb3h6eG5QNmtYNFBadnNIRERYQVRVNmU3ZHJ6eHhEYjVvMkpZUHBwVk1sMG45LTJUai1Dcy1SRG5WOW4yZnlrbjdvaXpTc1VQdHVfalRSU0N5Smt4WnFJTDJlejVuSTFwNVJuX3dDNktaS1AzbEtMN1BYeGNLVUNMdW5tWms?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fractyl Health, Inc. (GUTS) Moves to Buy: Rationale Behind the Upgrade", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOTE5NSm5IU1Z0RzBlazVjVHBEaF9tMVBkUmE2bUwxczRWR3RsOTItYzlaNWZpS3Vsel9ScmNSZXBHWWttR082ZmtVVzlLalJsd1RZRFFQUFBSVVRyMVM0ckw2bEFmbU9Tdnp2Wld5eG9uNGhhYXkwbUI5dS05eGZyVQ?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 70, "sentiment_summary": {"positive": 25, "negative": 7, "neutral": 38, "score": 58, "total": 70, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 21.05, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 12.39, "count": 23}, {"event": "analyst", "label": "Analyst action", "weight": 4.95, "count": 9}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 25, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 0.79, "latest_week": "2026-07-10", "one_week_move": 4.0, "four_week_move": -6.7, "twelve_week_move": 39.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.311631, "market_dynamics_buy_signal": false, "relative_strength": -39.493113, "fair_value_gap": -69.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "positive", "expectation_probability": 55.8836, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.0% over one week, -6.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 11}, {"label": "TradingView", "count": 6}, {"label": "Investing.com", "count": 4}, {"label": "Quiver Quantitative", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 63}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 23}, {"label": "Analyst action", "count": 9}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "63", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+4.0% over one week, -6.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "H.C. Wainwright reiterates Buy on Fractyl Health stock at $8"}], "updated_at": "2026-07-16T10:35:47.296481+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}